Clinical DevelopmentManagement is pausing the development in r/r AML for better strategic positioning, potentially delaying progress in another important segment.
Regulatory ApprovalAnalyst lowers price target to $6 from $15, reflecting a later FDA and EMA approval expectation of tuspetinib in AML.
Share DilutionRecent share dilution increased the shares outstanding to approximately 13 million, up from 7 million, which could impact shareholder value.